65,437 trials
Head and Neck Cancer
Primary: Participants With Mucositis and Hematological Toxicities With the Addition of Radioprotector Amifostine — 16 participants
Breast Cancer · Radiation Dermatitis
Primary: Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy — 15; 15; 15; 15 participants
Open Angle Glaucoma · Ocular Hypertension
Primary: Least Squares Mean Intraocular Pressure (IOP) at 8AM in the Study Eye — 16.6129; 21.2320 mmHg — p=<0.0001
Allergic Asthma
Primary: Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge — 3.5; 2.4; 0.54; 2.4 Eosinophil percentage
Prostate Cancer
Primary: Number of Participants Progression Free at 1 Year — 13 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) for 0-12 hr — 0.170; 0.219; 0.230; 0.075 Liters — p=<0.0001
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population — 30.3; 55.7; 43.4; 31.3…
Coronary Angiography
Primary: Volume (Percentage) of Contrast Media (CM) Diverted (Saved) in a Total Procedure — 47.4 percent of contrast media saved
Major Depressive Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15 — 35.6; 33.3; 36.8; 35.4 Units on a scale — p=< 0.001
Malocclusion · Class II Buccal Segment Relationship
Primary: Anchorage Loss Measured From 3-D Model Scanning — 0.80; 1.84; 1.36; 0.99 mm — p=0.05
Anemia
Primary: The Percentage of Participants Maintaining Average Haemoglobin (Hb) Concentration During the Efficacy Evaluation Period (EEP) Within the Target Range — 64.29; 57.14…
Myelogenous Leukemia, Chronic
Primary: Number of Participants With Complete Hematologic Response — 40 participants
Refractive Error
Primary: Mean Pre-lens Tear Lipid Layer Thickness After 2 Hours of Lens Wear on Day 1 — 61.2; 61.5 ICU
Endometriosis
Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
Hepatitis B, Chronic
Primary: Efficacy: Percent Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Titer at End of the Combination Treatment (Week 48) — 59.13 percent change